NCT03658213 (LARES) is a Phase 3 clinical trial of ZOLADEX 10.8 mg in Breast Cancer, sponsored by AstraZeneca.

Who is sponsoring NCT03658213?

NCT03658213 is sponsored by AstraZeneca.

What drugs are being tested in NCT03658213?

Interventions in NCT03658213: ZOLADEX 10.8 mg, ZOLADEX 3.6mg.

What condition does NCT03658213 study?

NCT03658213 studies Breast Cancer.

Is NCT03658213 still recruiting?

NCT03658213 is currently withdrawn. Last updated 10 May 2021.

Last reviewed 2021-05-10 · How we verify

NCT03658213: LARES

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.

Withdrawn Phase 3 Last updated 10 May 2021

What this trial tests

Phase 3 trial testing ZOLADEX 10.8 mg in Breast Cancer. Withdrawn.

Timeline

31 March 2020

Primary endpoint
4 November 2021

4 November 2021

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 3
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	31 March 2020
Primary completion	4 November 2021
Estimated completion	4 November 2021
Sites	11 locations across China

Drugs / interventions tested

ZOLADEX 10.8 mg — full drug profile →
ZOLADEX 3.6mg — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 59, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will recruit 168 patients in approximately 20 study centres in China. The primary objective of this study is to examine whether ZOLADEX 10.8 mg depot is non-inferior to ZOLADEX 3.6 mg depot in terms of the suppression rate of serum estradiol (E2) to the menopausal level (≤30 pg/mL) from Week 4 through Week 24.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women.
Lu YS, Wong A, Kim HJ. · · 2021 · cited 19× · PMID 34595110 · DOI 10.3389/fonc.2021.700722

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03658213 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 10 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03658213.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing